Ilyang Pharmaceutical Co.,Ltd Total Assets
Ilyang Pharmaceutical Co.,Ltd total assets. Based on the latest financial reports, Ilyang Pharmaceutical Co.,Ltd (007575) holds total assets worth ₩451.72 Billion KRW (≈ $306.13 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ilyang Pharmaceutical Co.,Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Ilyang Pharmaceutical Co.,Ltd (2014–2025)
Total assets of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025. This chart illustrates how Ilyang Pharmaceutical Co.,Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Ilyang Pharmaceutical Co.,Ltd for real-time trading data and today's change.
Ilyang Pharmaceutical Co.,Ltd - Asset Composition Analysis
Ilyang Pharmaceutical Co.,Ltd Total Assets Breakdown (December 2025)
Ilyang Pharmaceutical Co.,Ltd total assets breakdown as of December 2025. Ilyang Pharmaceutical Co.,Ltd's total assets of ₩451.72 Billion consist of 32.3% current assets and 67.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.2% |
| Accounts Receivable | ₩44.97 Billion | 9.8% |
| Inventory | ₩64.24 Billion | 14.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩25.75 Billion | 5.6% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Ilyang Pharmaceutical Co.,Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Ilyang Pharmaceutical Co.,Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ilyang Pharmaceutical Co.,Ltd's current assets represent 32.3% of total assets in 2025, a decrease from 36.8% in 2014.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, up from 3.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 14.1% of total assets.
Ilyang Pharmaceutical Co.,Ltd Competitors by Total Assets
Key competitors of Ilyang Pharmaceutical Co.,Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Ilyang Pharmaceutical Co.,Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 0.87 | 1.00 |
| Quick Ratio | 0.44 | 0.42 | 0.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-19.02 Billion | ₩-20.45 Billion | ₩-653.57 Million |
Ilyang Pharmaceutical Co.,Ltd - Advanced Valuation Insights
This section examines the relationship between Ilyang Pharmaceutical Co.,Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.1% |
| Total Assets | ₩457.33 Billion |
| Market Capitalization | $83.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ilyang Pharmaceutical Co.,Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ilyang Pharmaceutical Co.,Ltd's assets grew by 6.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ilyang Pharmaceutical Co.,Ltd (2014–2025)
The table below shows the annual total assets of Ilyang Pharmaceutical Co.,Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩457.33 Billion ≈ $309.93 Million |
+6.10% |
| 2024-12-31 | ₩431.03 Billion ≈ $292.10 Million |
+20.85% |
| 2023-12-31 | ₩356.66 Billion ≈ $241.70 Million |
-28.41% |
| 2022-12-31 | ₩498.19 Billion ≈ $337.61 Million |
+0.79% |
| 2021-12-31 | ₩494.27 Billion ≈ $334.96 Million |
+12.56% |
| 2020-12-31 | ₩439.12 Billion ≈ $297.58 Million |
+0.38% |
| 2019-12-31 | ₩437.46 Billion ≈ $296.46 Million |
+1.20% |
| 2018-12-31 | ₩432.25 Billion ≈ $292.93 Million |
-0.94% |
| 2017-12-31 | ₩436.37 Billion ≈ $295.72 Million |
+1.19% |
| 2016-12-31 | ₩431.26 Billion ≈ $292.26 Million |
-0.08% |
| 2015-12-31 | ₩431.63 Billion ≈ $292.51 Million |
+0.18% |
| 2014-12-31 | ₩430.83 Billion ≈ $291.97 Million |
-- |
About Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more